Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Nov 11;10:6997–7018. doi: 10.2147/IJN.S86592

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Detection of in vivo labeling by USPIO-CD133 Ab in CD133-positive subcutaneous xenografts by MRI.

Notes: (A) Photographs of CD133^high and CD133^low HT29 subcutaneous xenografts after subcutaneous inoculation of FACS-sorted CD133^high and CD133^low HT29 cells (Ai). H&E staining and differential CD133 immunostaining in CD133^low (Aii and Aiv) and CD133^high (Aiii and Av) xenografts at 400× magnification. (B) Gradient-echo (GRE) and multiple echo recombined gradient echo (Merge) images of CD133^high and CD133^low HT29 subcutaneous xenografts were acquired before (Bi and Biii, preinjection) and after (Bii and Biv, postinjection) intravenous injection of USPIO-CD133 Ab for 24 hours. (C) The representative signal drop ratio of MR images, including T2WI (Ci), multiecho GRE image (Cii), and Merge image (Ciii) after USPIO-CD133 Ab injection. Bar, SE; *P<0.05. (D) CD133 immunohistochemical analysis showed that the CD133^high xenografts (Di) demonstrated stronger CD133 expression than the CD133^low xenografts (Dii) at 400× magnification. When compared to CD133^low xenografts (Diii), CD133^high xenografts (Div) accumulated more iron as seen by Prussian blue staining at 1,000× magnification.

Abbreviations: FACS, fluorescence-activated cell sorting; GRE, gradient-echo; H&E, hematoxylin and eosin; Merge, multiple echo recombined gradient echo; MRI, magnetic resonance imaging; SE, standard error of the mean; T2WI, T2 weighted image; USPIO-CD133 Ab, ultrasmall superparamagnetic iron oxide conjugated with anti-CD133 antibodies.

Detection of in vivo labeling by USPIO-CD133 Ab in CD133-positive subcutaneous xenografts by MRI.

Notes: (A) Photographs of CD133^high and CD133^low HT29 subcutaneous xenografts after subcutaneous inoculation of FACS-sorted CD133^high and CD133^low HT29 cells (Ai). H&E staining and differential CD133 immunostaining in CD133^low (Aii and Aiv) and CD133^high (Aiii and Av) xenografts at 400× magnification. (B) Gradient-echo (GRE) and multiple echo recombined gradient echo (Merge) images of CD133^high and CD133^low HT29 subcutaneous xenografts were acquired before (Bi and Biii, preinjection) and after (Bii and Biv, postinjection) intravenous injection of USPIO-CD133 Ab for 24 hours. (C) The representative signal drop ratio of MR images, including T2WI (Ci), multiecho GRE image (Cii), and Merge image (Ciii) after USPIO-CD133 Ab injection. Bar, SE; *P<0.05. (D) CD133 immunohistochemical analysis showed that the CD133^high xenografts (Di) demonstrated stronger CD133 expression than the CD133^low xenografts (Dii) at 400× magnification. When compared to CD133^low xenografts (Diii), CD133^high xenografts (Div) accumulated more iron as seen by Prussian blue staining at 1,000× magnification.

Abbreviations: FACS, fluorescence-activated cell sorting; GRE, gradient-echo; H&E, hematoxylin and eosin; Merge, multiple echo recombined gradient echo; MRI, magnetic resonance imaging; SE, standard error of the mean; T2WI, T2 weighted image; USPIO-CD133 Ab, ultrasmall superparamagnetic iron oxide conjugated with anti-CD133 antibodies.